Welcome to our April roundup of the most relevant and interesting content shared on this platform. April 2026 has been a particularly rich month, with significant news on the diagnostics, clinical trials and treatment front alongside important research on quality of life, patient preferences information, economic burden. There is also a selection of patient resources and community initiatives from across the global pulmonary hypertension network. We hope you find something useful and inspiring.
👇 Scroll down for the April highlights, organised by category.
Clinical Trials and treatments for PAH, PH-LHD & PH-ILD
- Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD): State-of-the-Art Review — European Respiratory Journal, 2026
- Congenital Heart Disease and pulmonary arterial hypertension: Current Perspectives — Review of Cardiovascular Medicine, March 20, 2026
- Review of pulmonary arterial hypertension Research in 2025: Key Trends and What They Mean for Patients — Pulmonary Therapy, April 8, 2026
- Sotatercept for WHO Group 2 pulmonary hypertension: Results from the Phase 2 CADENCE Study — Circulation, March 29, 2026
- Inhibikase Therapeutics Begins Pivotal Phase 3 Trial in pulmonary arterial hypertension (PAH) — April 7, 2026
- AllRock Bio Doses First Patients in Phase 2a Trial of ROC-101 for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) — April 9, 2026
- Cereno Scientific Reports Favourable Safety After 12 Months of CS1 Treatment in pulmonary arterial hypertension — Expanded Access Program, March 31, 2026
- Promising Results for Nebulised Treprostinil (Tyvaso) in pulmonary hypertension associated with interstitial lung disease (PH-ILD, WHO Group 3)
- A Case Report on Initial Triple Combination Therapy Including sotatercept in Severe idiopathic pulmonary arterial hypertension (PAH) — ERJ Open Research, March 30, 2026
- CardioMEMS-Guided Therapy Shows Promising Results in pulmonary arterial hypertension (PAH): ARTISAN Interim Analysis at ACC 2026 — American College of Cardiology Congress, March 28–30, 2026
Diagnostics
- New Blood Markers Show Promise for WHO Group 2 Pulmonary Hypertension — Pulmonary Hypertension News, March 23, 2026
- Detecting Pulmonary Hypertension Earlier? FDA Clears Anumana’s AI Echocardiogram Algorithm — PH-KSP
Industry update
- GSK Completes Acquisition of 35Pharma — GSK press release
- Pulnovo Medical and Medtronic Join Forces to Advance Pulmonary Artery Denervation (PADN) for PH — Pulse 2.0, April 25, 2026
Economic burden of PAH
- Economic Burden of pulmonary arterial hypertension in Switzerland — PLOS ONE, April 28, 2026
Organ Donation and Transplant
- 15,000 km, 177 Days, 5 Countries, One Mission: Lukáš Jakovec Keeps Pedalling for our “Wheels of Hope” Campaign
- Progress on Xenotransplantation and Bioengineered Organs: The Potential Next Growth Frontier for United Therapeutics
- The Latest Edition of PHA Canada’s Magazine “Connections” is Dedicated to Organ Donation and Transplant — PHA Canada
Digital Health & Innovation
- Exploring the Potential of Synthetic Control Arms in Clinical Trials — The Scientist, April 25, 2026
Quality of life and patient preference information
- Self-Image and Pulmonary Hypertension: How Does Living with the Condition Shape the Way You See Yourself? — PHA UK
- Study suggests pulmonary arterial hypertension extends beyond the cardiopulmonary system to affect brain structure and memory — Nature Scientific Reports, April 3, 2026
- Quality of Life in Patients with pulmonary arterial hypertension: A Systematic Review and Meta-Analysis — Health and Quality of Life Outcomes, April 13, 2026
- The New FDA Guidance on Incorporating Patient Preference Information — What It Means for Patient Organisations — March 30, 2026
Patient Resources & Community
- The US PHA Celebrates its 35th Anniversary — Read the Latest Edition of Pathlight — PHA US
- Pulmonary Hypertension Global Patient Survey (PHGPS) — Key Insights and Campaign Pack — PH-KSP
- Join the Global Pulmonary Hypertension Patient Hackathon — June 10–11, 2026! — GAAPP & Latin Health Leaders
- PHA Canada Launches its pulmonary hypertension “Peer Mentor Program” — PHA Canada, April 2026
- PHA Canada Launches an Advisory Council of Patients and Caregivers — PHA Canada
- UK Pulmonary Hypertension Association Opens Poetry Competition to the PH Community — PHA UK
- Understanding How Right Heart Catheterisation Works — PHA UK’s Video of the Month — PHA UK, April 2026
- Walk4PH Nigeria: A Community Steps Up for pulmonary hypertension Awareness — Cardiac Community announcement